Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab plus budigalimab and chemotherapy versus pembrolizumab plus chemotherapy in untreated metastatic non-squamous NSCLC
jRCT2031240062Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised trial of livmoniplimab, budigalimab, pembrolizumab and pemetrexed in non-small cell lung cancer (NSCLC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Best Overall Response of complete response/partial response and Overall survival. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240062.